(MedPage Today) -- Regorafenib (Stivarga), an inhibitor of multiple kinase enzymes, has been approved for use in treatment-refractory, metastatic colorectal cancer, the FDA announced Thursday. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment